With seven approved drugs for overactive bladder already on the market, the potential for new treatments might seem to be limited. The reality is that OAB treatment is still not optimal.
PI-RADS update does not improve Gleason grade discordance between MRI-targeted biopsy and radical prostatectomy
“Implementation of the most recent PI-RADS update did not improve the incongruence in prostate cancer grade assessment between MRI/ultrasound fusion targeted biopsy and surgery,” the authors wrote.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Dr. Siefker-Radtke highlights the latest erdafitinib research in urothelial carcinoma
"It is erdafitinib’s time to shine," says Arlene O. Siefker-Radtke, MD.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
EpiSwitch Prostate Screening blood test launches on US market
The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.
Revolutionizing Prostate Cancer Imaging with PSMA PET-CT
In the first article of this series, Naveen Kella, MD, discusses the transformative impact of PSMA PET-CT imaging on prostate cancer diagnosis, highlighting its advantages and addressing clinical challenges and guidelines in this evolving field.
2 Clarke Drive Cranbury, NJ 08512